Level Four Advisory Services LLC Boosts Holdings in Medtronic PLC $MDT

by · The Cerbat Gem

Level Four Advisory Services LLC increased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 2.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 42,526 shares of the medical technology company’s stock after buying an additional 1,074 shares during the quarter. Level Four Advisory Services LLC’s holdings in Medtronic were worth $3,707,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in MDT. Bank of Nova Scotia Trust Co. raised its position in Medtronic by 0.9% in the second quarter. Bank of Nova Scotia Trust Co. now owns 111,420 shares of the medical technology company’s stock valued at $9,712,000 after purchasing an additional 956 shares during the period. Patrick M Sweeney & Associates Inc. increased its position in shares of Medtronic by 2.9% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 7,154 shares of the medical technology company’s stock worth $632,000 after purchasing an additional 200 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Medtronic by 1.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 162,624 shares of the medical technology company’s stock valued at $14,176,000 after buying an additional 2,313 shares during the period. Elevation Point Wealth Partners LLC lifted its position in Medtronic by 3.6% in the second quarter. Elevation Point Wealth Partners LLC now owns 15,842 shares of the medical technology company’s stock valued at $1,381,000 after buying an additional 551 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in Medtronic by 27.4% in the second quarter. Quadrant Capital Group LLC now owns 15,185 shares of the medical technology company’s stock valued at $1,324,000 after buying an additional 3,267 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MDT shares. Wells Fargo & Company lifted their price target on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. UBS Group lifted their target price on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. Jefferies Financial Group restated a “hold” rating and set a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.72.

View Our Latest Analysis on Medtronic

Medtronic Price Performance

Shares of MDT opened at $104.53 on Friday. The company has a market cap of $134.07 billion, a P/E ratio of 28.79, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm’s 50 day moving average price is $96.06 and its 200 day moving average price is $91.61.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company posted $1.26 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

About Medtronic

(Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Stories